Month: 2026 年 1 月

AUSTRALIA’S FINEST REAL ESTATE EMERGES VICTORIOUS DURING CULMINATION OF THE 2025 PROPERTYGURU ASIA PROPERTY AWARDS SERIESBANGKOK, Jan 13, 2026 - (ACN Newswire via SeaPRwire.com) - The 20th edition of the PropertyGuru Asia Property Awards series has culminated in spectacular style at its Grand Final, distinguishing sublime achievements by development companies from Australia.After a landmark journey through 13 property markets, the 2025 PropertyGuru Asia Property Awards Grand Final set apart Asia’s outstanding developers, developments, and designs in ceremonies today at The Athenee Hotel, a Luxury Collection Hotel, Bangkok.Commemorating 20 years of recognising achievements in real estate, the PropertyGuru Asia Property Awards Grand Final featured over 90 categories celebrating the “Best in Asia,” in line with PropertyGuru’s vision of powering communities to live, work, and thrive in tomorrow’s cities. Finalists were chosen from the PropertyGuru Asia Property Awards’ series of galas and events across the region.Eterno Property Group represented Australia’s enduring cross-border appeal to property seekers with wins for its projects Munro House and The Newlands. Munro House won Best Completed Condo Development (Asia) while The Newlands won Best Nature Integrated Development (Asia). Meanwhile, Eve Residences by Homecorp was recognised as Best Oceanview Condo Development (Asia).Henderson Land Development Company Limited from Hong Kong brought home the prestigious golden statuette of Best Developer (Asia). The Legacy - 8 Castle Road, Mid Levels, Henderson Land Development Company Limited’s ultra-luxurious joint venture with leading developer New World Development Company Limited, achieved a double victory in the development and design categories.One Central Macau Revamp by Properties Sub F, Limited, a joint venture of Hongkong Land Group and Shun Tak Development Limited, also won and represented the Chinese special administrative regions. Design innovation from Mainland China was prominently recognised this year, with wins for top design practices Benoy, CAN Design, J&A Design, and Lead8.With a total of 17 Best in Asia titles, Malaysia was the top-performing country at the 2025 PropertyGuru Asia Property Awards Grand Final. JLand Group emerged victorious as Best Industrial Developer (Asia), winning for its township development Bandar Dato’ Onn. MTD Properties and Faire Development were named Best Affordable Residential Developer (Asia) and Best Breakthrough Developer (Asia), respectively.Malaysia’s honours were spread across diverse developments emphasising connectivity, sustainability, multi-generational flexibility, and premium living experiences. Other winning companies included Armani Group; Astaka Kimlun Sdn Bhd; City Motors Group; Exal (Malaysia) Sdn Bhd; Gunung Impian Development Sdn Bhd; IIB Land Sdn. Bhd.; Malton Berhad; Perbadanan Kemajuan Negeri Selangor (PKNS); Platinum Victory; R&F Development Sdn Bhd; Sime Darby Property; and TRX City Sdn Bhd.Indonesia followed closely with 15 wins for developers across the archipelago. Winners demonstrated their prowess in building live-work-play communities, with Paramount Land named Best Township Developer (Asia) and Sinar Mas Land winning for the townships BSD City and Grand Wisata. Sinar Mas Land also scored a joint win with Hongkong Land for Botanic Villa at NavaPark.PT. Putragaya Wahana, hailed Best Commercial Developer (Asia), earned multiple wins for the superblock Thamrin Nine, home to Indonesia’s tallest buildings. Winning projects by Mandiri Land, Masgroup, Summarecon Group, and Triniti Land set high benchmarks for affordable, mid-end, high-end, and eco-conscious living, as well as hospitality.With 14 wins, developers from Vietnam rose as another formidable force at the Grand Final, led by CapitaLand Development (Vietnam), winner of Best Sustainable Developer (Asia) and multiple honours for the projects Orchard Grand, Orchard Mansion, The Fullton, and The Orchard. Gamuda Land Vietnam won Best Community Developer (Asia), reinforced by projects such as Central Park and Springville. Nomura Real Estate Vietnam, awarded Best International Partner Developer (Asia), was additionally recognised for The Komorebi. Projects from Ecopark Founder and KD Investment Joint Stock Company rounded out the elite winners from Vietnam.Singapore developers received 11 wins, including Best Residential Developer (Asia) for UOL Group Limited. Parktown Residence, a venture of CapitaLand Development, UOL Group Limited, and Singapore Land Group Limited, scored three wins while Upperhouse at Orchard Boulevard delivered a joint win for UOL Group Limited and Singapore Land Group Limited. IOI Properties Singapore meanwhile achieved three wins across the projects IOI Central Boulevard Towers and W Residences Marina View. Honours for Allgreen Properties and The Assembly Place further underscored real estate excellence in the city-state.Developers across the Philippines won 10 Best in Asia titles. Robinsons Land received four titles, including the Best Luxury Developer (Asia) award and wins for The Mall | NUSTAR; The Victor at Bridgetowne; and work.able GBF Center 1. Robinsons Hotels and Resorts was named Best Hospitality Developer (Asia) while RLC Residences, a Robinsons Land subsidiary, won for Sync and The Residences at The Westin Manila. Winning developments from Aboitiz Economic Estates, Aboitiz Land, Inc., and FIESTA Communities Incorporated showcased the Philippines’ impressive progress in industrial development and housing connectivity.Thailand developers earned seven Best in Asia wins, led by Reignwood Group, winner of Best Luxury Mega Township Development (Asia) for Reignwood Park. Thailand’s wins underlined development innovations and architectural excellence throughout the kingdom, exemplified by luxurious homes and coastal residences by AP (Thailand) Public Company Limited, Pruksa Real Estate Public Company Limited, Triya, and Tropical Life Real Estate Co., Ltd. Solidifying Thailand's stature as a premier retail destination, Lead8 was honoured for its design on Parade at One Bangkok.Supaluck Umpujh, chairwoman of The Mall Group, received the PropertyGuru Icon Award from the editorial team of Property Report by PropertyGuru. The 2017 Thailand Real Estate Personality of the Year returned to the PropertyGuru Asia Property Awards in recognition of her recent iconic achievements in mixed-use and retail development, including the award-winning EM District in Bangkok.From Japan, JY Suites Tsutenkaku by Jean Yip Developments won the Best Affordable Condo Development (Asia) award while Four Seasons Hotel Osaka by Curiosity won Best Hospitality Interior Design (Asia).Representing Sri Lanka, Home Lands Group of Companies was named Best Lifestyle Developer (Asia) while Pentara Model Apartment by Urbanspace Interiors Pvt Ltd. won Best Condo Interior Design (Asia).From the Middle East, The Chedi Private Residences, Sheikh Zayed Road, Dubai, United Arab Emirates by Chedi Hospitality won Best Branded Residential Development (Asia).Jules Kay, general manager of PropertyGuru Asia Property Awards and Events, said: “We conclude the landmark 20th edition of the PropertyGuru Asia Property Awards series on a highly positive note, echoing industry resilience in over 600 awards across 13 distinct real estate markets that continue to overcome headwinds and capitalise on strategic opportunities in the current cycle. This year’s Best in Asia winners showcase record-setting skyscrapers, large-scale townships, transit-oriented developments, premium and affordable homes, flexible spaces, and urban landmarks, designed with ambition for long-term value and guided by environmental and social considerations. We look forward to the new standards of sustainable development that developers in Asia will deliver over the next 20 years.”Thien Duong, chairperson of the Grand Final jury and general director, GroupGSA (Vietnam), said: “The distinguished winners of the 20th PropertyGuru Asia Property Awards Grand Final have expertly answered the regional demand for experiential living, wellness integration, and future-proofed design. From integrated live-work-play communities to ultra-luxurious addresses and immersive sales galleries, the collective momentum is toward more sustainable, people-centric, and technologically adaptive projects. Our awardees demonstrate that exceptional master-planning, architecture, interior design, and landscaping can be achieved at any scale, ultimately driving tenant retention, buyer attraction, and the creation of civic assets that enrich the urban fabric. Congratulations to the Best in Asia.”The winners were selected by a jury comprising the head judges of participating markets in the Awards: Thien Duong; Ajai A Kapoor, CEO, 360 degrees – Real Estate Services (India); Cyndy Tan Jarabata, president of TAJARA Leisure & Hospitality Group Inc. (Philippines); Doddy A. Tjahjadi, managing director, PTI Architects (Indonesia); Eddie Guillemette, CEO, Midori no Ki (Japan); Datuk Ar. Ezumi Harzani Ismail, president, Malaysian Institute of Architects: 2020-2022 (Malaysia); Ivan Lam, executive director, international business, Charter Keck Cramer (Australia); Ken Ip, chairman, Asia MarTech Society (Mainland China); Dr. Nirmal De Silva, director and CEO, Paramount Realty (Sri Lanka); Paul Tse, president, Macao Association of Building Contractors and Developers (Hong Kong and Macau); Roy Ling, CEO, board director, and adjunct professor, FollowTrade (Singapore); and Suphin Mechuchep, strategic real estate advisor (Thailand).HLB, the global network of independent professional accounting firms and business advisers, upheld the integrity of the awards. Paul Ashburn of HLB International Real Estate Group and Sakanphon Fueangwong of HLB Thailand oversaw the selection process.The PropertyGuru Asia Property Awards Grand Final is supported by platinum sponsor Sub-Zero & Wolf SEA; official portal partner PropertyGuru; official magazine Property Report by PropertyGuru; media partners Bridges, BusinessWorld, d+a Magazine, Detik.com, Hot Magazine, Inquirer Property, Kompas.com, Kopi and Property, Luxury Society of Asia, Manila Bulletin, Niaga Times, Penang Property Talk, Prop2morrow, REm Thailand, SquareRooms, Tatler Asia Homes, TerraBKK, The Grid, The Malaysia Voice, The Philippine Star, and Top10 of Asia; official courier EZY Express; and official supervisor HLB.For more information, email awards@propertyguru.com or visit the official website: AsiaPropertyAwards.com.COMPLETE LIST OF WINNERS20th PropertyGuru Asia Property Awards Grand FinalDEVELOPER AWARDSBest Developer (Asia)Henderson Land Development Company Limited – China – Hong Kong and Macau (WINNER)Eterno Property Group – AustraliaHome Lands Group of Companies – Sri LankaJean Yip Developments – JapanJLand Group – MalaysiaRobinsons Land – PhilippinesSummarecon Group – IndonesiaBest Township Developer (Asia)Paramount Land – Indonesia (WINNER)Phu Long Real Estate Corporation – VietnamBest Luxury Developer (Asia)Robinsons Land – Philippines (WINNER)Allgreen Properties Limited – SingaporeSkyland Group – AustraliaBest Commercial Developer (Asia)PT. Putragaya Wahana – Indonesia (WINNER)Robinsons Offices – PhilippinesBest Industrial Developer (Asia)JLand Group – Malaysia (WINNER)Aboitiz Economic Estates – PhilippinesBest Hospitality Developer (Asia)Robinsons Hotels and Resorts – Philippines (WINNER)Best Lifestyle Developer (Asia)Home Lands Group of Companies – Sri Lanka (WINNER)Jean Yip Developments – JapanBest Sustainable Developer (Asia)CapitaLand Development (Vietnam) – Vietnam (WINNER)Berinda Group – MalaysiaRobinsons Land – PhilippinesUOL Group Limited – SingaporeBest Residential Developer (Asia)UOL Group Limited – Singapore (WINNER)Best Affordable Residential Developer (Asia)MTD Properties – Malaysia (WINNER)FIESTA Communities Incorporated – PhilippinesKim Oanh Land – VietnamBest Community Developer (Asia)Gamuda Land Vietnam – Vietnam (WINNER)Best Breakthrough Developer (Asia)Faire Development – Malaysia (WINNER)Apex Asia Development Pte. Ltd. – SingaporeBest International Partner Developer (Asia)Nomura Real Estate Vietnam – Vietnam (WINNER)DEVELOPMENT AWARDSBest Mega Township Development (Asia)BSD City by Sinar Mas Land – Indonesia (WINNER)Kota Baru Parahyangan by PT Belaputera Intiland – IndonesiaBest Luxury Mega Township Development (Asia)Reignwood Park by Reignwood Group – Thailand (WINNER)Best Township Development (Asia)Bandar Dato’ Onn by JLand Group – Malaysia (WINNER)One Era by Hoa Lan Township JVC – VietnamSummarecon Bandung by Summarecon Group – IndonesiaSummarecon Serpong by Summarecon Group – IndonesiaBest Mixed Use Development (Asia)Tun Razak Exchange by TRX City Sdn Bhd – Malaysia (WINNER)Avia Estate by Alsons Development and Investment Corporation – PhilippinesHighwood - 70 To Kwa Wan Road by Henderson Land Development Company Limited – China – Hong Kong and MacauParktown Residence by CapitaLand Development, UOL Group Limited, & Singapore Land Group Limited – SingaporeBest Completed Mixed Use Development (Asia)Thamrin Nine by PT. Putragaya Wahana – Indonesia (WINNER)Best Industrial Development (Asia)LIMA Estate by Aboitiz Economic Estates – Philippines (WINNER)Industropolis Batang SEZ by PT Kawasan Industri Terpadu Batang – IndonesiaBest Lifestyle Commercial Development (Asia)Agora at Thamrin Nine by PT. Putragaya Wahana – Indonesia (WINNER)Odeon by UOL Group Limited – SingaporeBest Green Commercial Development (Asia)One Central Macau Revamp by Properties Sub F, Limited (Joint Venture of Hongkong Land Group & Shun Tak Development Limited) – China – Hong Kong and Macau (WINNER)GBF Centers 1 & 2 by Robinsons Offices – PhilippinesBest Eco Friendly Commercial Development (Asia)Teras Lakon at Summarecon Serpong by Summarecon Group – Indonesia (WINNER)Best Office Development (Asia)IOI Central Boulevard Towers by IOI Properties Singapore – Singapore (WINNER)Luminary Tower at Thamrin Nine by PT. Putragaya Wahana – IndonesiaYokohama Symphostage by Obayashi Corporation – JapanBest Retail Development (Asia)JLC by CAN Design – Mainland China (WINNER)Jakarta Premium Outlets by Genting Simon Group – IndonesiaBest Lifestyle Retail Development (Asia)The Mall | NUSTAR by Robinsons Land – Philippines (WINNER)Best Hospitality Development (Asia)Holiday Inn Resort Bintan Lagoi Beach by Mandiri Land – Indonesia (WINNER)Best City Hotel Development (Asia)Holiday Inn KL Bangsar by City Motors Group – Malaysia (WINNER)Fili Hotel Bridgetowne by Robinsons Hotels and Resorts – PhilippinesSocial on Outram by The Assembly Place – SingaporeBest Ultra Luxury Condo Development (Asia)Armani Hallson KLCC by Armani Group – Malaysia (WINNER)W Residences Marina View – Singapore by IOI Properties Singapore – SingaporeBest Luxury Condo Development (Asia)Upperhouse at Orchard Boulevard by UOL Group Limited & Singapore Land Group Limited – Singapore (WINNER)Pentara Residencies - Thummulla Handiya "The Address in Colombo" by Home Lands Group of Companies – Sri LankaBest Condo Development (Asia)Parktown Residence by CapitaLand Development, UOL Group Limited, & Singapore Land Group Limited – Singapore (WINNER)33–47A Elgin Street by Henderson Land Development Company Limited – China – Hong Kong and MacauBest Completed Ultra Luxury Condo Development (Asia)The Legacy - 8 Castle Road, Mid Levels by Henderson Land Development Company Limited & New World Development Company Limited – China – Hong Kong and Macau (WINNER)Best Completed Luxury Condo Development (Asia)The Residences at The Westin Manila by RLC Residences – Philippines (WINNER)Best Completed Condo Development (Asia)Munro House by Eterno Property Group – Australia (WINNER)Santorini Resort Apartments & Residencies, Negombo by Home Lands Group of Companies – Sri LankaBest Waterfront Condo Development (Asia)Central Park by Gamuda Land Vietnam – Vietnam (WINNER)Bayfonte Marina Resort Apartments & Villas, Negombo by Home Lands Group of Companies – Sri LankaChapter Charoenkrung Riverside by Pruksa Real Estate Public Company Limited – ThailandWanda View by 16MC Developments – AustraliaBest Lifestyle Condo Development (Asia)W Residences Marina View – Singapore by IOI Properties Singapore – Singapore (WINNER)The Zenith by Xiangyuan Property Development Limited – China – Hong Kong and MacauBest Mid End Condo Development (Asia)Sync by RLC Residences – Philippines (WINNER)Best High End Condo Development (Asia)Orchard Grand by CapitaLand Development (Vietnam) – Vietnam (WINNER)Best Connectivity Condo Development (Asia)Linkar 52 by Perbadanan Kemajuan Negeri Selangor (PKNS) – Malaysia (WINNER)Best Luxury Lifestyle Condo Development (Asia)Arden Serviced Residence by Astaka Kimlun Sdn Bhd – Malaysia (WINNER)Best Oceanview Condo Development (Asia)Eve Residences by Homecorp – Australia (WINNER)Best Affordable Condo Development (Asia)JY Suites Tsutenkaku by Jean Yip Developments – Japan (WINNER)Best Investment Condo Development (Asia)R&F Princess Cove Phase 2 - Seine Region by R&F Development Sdn Bhd – Malaysia (WINNER)Best Multigeneration Living Condo Development (Asia)PV22 Residences by Platinum Victory – Malaysia (WINNER)Best Ultra Luxury Housing / Landed Development (Asia)Botanic Villa at NavaPark by PT. Bumi Parama Wisesa (Hongkong Land & Sinar Mas Land) – Indonesia (WINNER)Best Luxury Housing / Landed Development (Asia)The Fullton by CapitaLand Development (Vietnam) – Vietnam (WINNER)Ardea at Summarecon Serpong by Summarecon Group – IndonesiaMatera Signature by Paramount Land – IndonesiaSango Project by Sango Construction Co., Ltd. – JapanBest Housing / Landed Development (Asia)Orchard Mansion by CapitaLand Development (Vietnam) – Vietnam (WINNER)Narra Park Residences Avia by Alsons Development and Investment Corporation – PhilippinesSpringleaf Collection by The Assembly Place – SingaporeUniversity Road Developments by Jean Yip Developments – SingaporeBest Affordable Housing / Landed Development (Asia)Areum Parc Bogor by Masgroup – Indonesia (WINNER)Sunnyhomes by SMDC Symphony Homes – PhilippinesBest Waterfront Housing / Landed Development (Asia)Seafront Residences by Aboitiz Land, Inc. – Philippines (WINNER)Best High End Housing / Landed Development (Asia)Bukit Impian Residence by Gunung Impian Development Sdn Bhd – Malaysia (WINNER)Best Mid End Housing / Landed Development (Asia)Vanica Residence at Summarecon Crown Gading by Summarecon Group – Indonesia (WINNER)baé by Faire Development – MalaysiaBest Luxury Lifestyle Housing / Landed Development (Asia)The Palazzo Pinklao - Borom by AP (Thailand) Public Company Limited – Thailand (WINNER)Best Lifestyle Housing / Landed Development (Asia)European Island, Eco Central Park by Ecopark Founder – Vietnam (WINNER)Giva at The Kaia by Sinar Mas Land – IndonesiaPonderosa Vista by Berinda Group – MalaysiaBest Completed Housing / Landed Development (Asia)The Orchard by CapitaLand Development (Vietnam) – Vietnam (WINNER)Best Eco Friendly Housing Development (Asia)Elmina Ridge 1 by Sime Darby Property – Malaysia (WINNER)Best Oceanview Housing / Landed Development (Asia)Nathee/Thawee by Tropical Life Residence by Tropical Life Real Estate Co., Ltd. – Thailand (WINNER)Best Multigeneration Living Housing / Landed Development (Asia)SÓL Estate Prime by Exal (Malaysia) Sdn Bhd – Malaysia (WINNER)Best Connectivity Housing / Landed Development (Asia)FIESTA Communities Aguso by FIESTA Communities Incorporated – Philippines (WINNER)Best Townhouse Development (Asia)Springville by Gamuda Land Vietnam – Vietnam (WINNER)Aludra Residensi by Perbadanan Kemajuan Negeri Selangor (PKNS) – MalaysiaBest Branded Residential Development (Asia)The Chedi Private Residences, Sheikh Zayed Road, Dubai, United Arab Emirates by Chedi Hospitality – Middle East (WINNER)Best Wellness Residential Development (Asia)The Komorebi by Nomura Real Estate Vietnam – Vietnam (WINNER)Best Nature Integrated Development (Asia)The Newlands by Eterno Property Group – Australia (WINNER)The Hood at Summarecon Serpong by Summarecon Group – IndonesiaBest Serviced Apartment Development (Asia)Park Green Pavilion Bukit Jalil by Malton Berhad – Malaysia (WINNER)DESIGN AWARDSBest Township Masterplan Design (Asia)Grand Wisata by Sinar Mas Land – Indonesia (WINNER)Taman Impian Emas by Gunung Impian Development Sdn Bhd – MalaysiaBest Mixed Use Architectural Design (Asia)Nanjing Alibaba Center by Benoy – Mainland China (WINNER)Menara Jakarta by ASRI - ( subsidiary of ASG ) Agung Sedayu Group – IndonesiaBest Office Architectural Design (Asia)IOI Central Boulevard Towers by IOI Properties Singapore – Singapore (WINNER)GBF Center 2 by Robinsons Offices – PhilippinesBest Retail Architectural Design (Asia)Shanghai Qianwan Incity MEGA by Lead8 – Mainland China (WINNER)K Mall at Menara Jakarta by ASRI - ( subsidiary of ASG ) Agung Sedayu Group – IndonesiaKato Knife Gallery and Workshop by BAUM Ltd. – JapanParade at One Bangkok by Lead8 – ThailandSKP Wuhan by Sybarite Architects – Mainland ChinaThe Mall | NUSTAR by Robinsons Land – PhilippinesBest Hospitality Architectural Design (Asia)Hotel Indigo Bintan Lagoi Beach by Mandiri Land – Indonesia (WINNER)ILUVIO Resort Motobu by K2-Design Architect & Associates Co., Ltd. – JapanBest Luxury Condo Architectural Design (Asia)Promenade Peak by Allgreen Properties Limited – Singapore (WINNER)Best Condo Architectural Design (Asia)Parktown Residence by CapitaLand Development, UOL Group Limited, & Singapore Land Group Limited – Singapore (WINNER)Best Ultra Luxury Housing / Landed Architectural Design (Asia)Triya Panwa by The Element by Triya – Thailand (WINNER)Best Luxury Housing / Landed Architectural Design (Asia)The Reserve Villas Sukhumvit 89/1 by Pruksa Real Estate Public Company Limited – Thailand (WINNER)Xandari at Summarecon Bandung by Summarecon Group – IndonesiaBest Housing / Landed Architectural Design (Asia)La Tiên Villa Subdivision – Libera Nha Trang by KD Investment Joint Stock Company – Vietnam (WINNER)The City Ratchapruek - Phrannok by AP (Thailand) Public Company Limited – ThailandBest High End Housing / Landed Architectural Design (Asia)Sequoia Hills – Cluster Harvest Ville by Triniti Land – Indonesia (WINNER)Best Affordable Housing / Landed Architectural Design (Asia)Areum Parc Bogor by Masgroup – Indonesia (WINNER)Best Townhouse Architectural Design (Asia)Wawari West Park Homes by IIB Land Sdn. Bhd. – Malaysia (WINNER)Best Sales Gallery Architectural Design (Asia)Galeria SA Sentral by Perbadanan Kemajuan Negeri Selangor (PKNS) – Malaysia (WINNER)Summarecon Bogor by Summarecon Group – IndonesiaW Residences Marina View – Singapore by IOI Properties Singapore – SingaporeBest Retail Interior Design (Asia)Parade at One Bangkok by Lead8 – Thailand (WINNER)Kato Knife Gallery and Workshop by BAUM Ltd. – JapanLiving World Kota Wisata Cibubur by PT Sahabat Kota Wisata (JV between Kawan Lama Group & Sinar Mas Land) – IndonesiaNanjing Jinling Place by Lead8 – Mainland ChinaThe Mall | NUSTAR by Robinsons Land – PhilippinesBest Office Interior Design (Asia)Shanghai Midea Global Innovation Park by J&A Design – Mainland China (WINNER)GBF Center 2 by Robinsons Offices – PhilippinesBest Hospitality Interior Design (Asia)Four Seasons Hotel Osaka by Curiosity – Japan (WINNER)25hours Hotel The Oddbird Jakarta by ASRI - ( subsidiary of ASG ) Agung Sedayu Group – IndonesiaILUVIO Resort Motobu by K2-Design Architect & Associates Co., Ltd. – JapanW Singapore - Marina View by IOI Properties Singapore – SingaporeBest Ultra Luxury Condo Interior Design (Asia)The Legacy - 8 Castle Road, Mid Levels by Henderson Land Development Company Limited & New World Development Company Limited – China – Hong Kong and Macau (WINNER)W Residences Marina View – Singapore by IOI Properties Singapore – SingaporeBest Luxury Condo Interior Design (Asia)Upperhouse at Orchard Boulevard by UOL Group Limited & Singapore Land Group Limited – Singapore (WINNER)Best Condo Interior Design (Asia)Pentara Model Apartment by Urbanspace Interiors Pvt Ltd. – Sri Lanka (WINNER)Best Housing / Landed Interior Design (Asia)Beon Kaset - Nawamin by AP (Thailand) Public Company Limited – Thailand (WINNER)Royale Residence by DM Projects Group – IndonesiaBest Commercial Landscape Design (Asia)Hotel Indigo Bintan Lagoi Beach by Mandiri Land – Indonesia (WINNER)Best Condo Landscape Design (Asia)Parktown Residence by CapitaLand Development, UOL Group Limited, & Singapore Land Group Limited – Singapore (WINNER)Best Housing / Landed Landscape Design (Asia)The Fullton by CapitaLand Development (Vietnam) – Vietnam (WINNER)Centro Sathorn - Suksawat by AP (Thailand) Public Company Limited – ThailandBest Townhouse Landscape Design (Asia)Springville by Gamuda Land Vietnam – Vietnam (WINNER)Wawari West Park Homes by IIB Land Sdn. Bhd. – MalaysiaBest Landmark Design (Asia)The Victor at Bridgetowne by Robinsons Land – Philippines (WINNER)Best Co Working Space (Asia)work.able GBF Center 1 by Robinsons Land – Philippines (WINNER)Best Co Living Space (Asia) Serene Living, managed by The Assembly Place – Singapore (WINNER)INDIVIDUAL AWARDPropertyGuru Icon AwardSupaluck Umpujh, Chairwoman, The Mall Group (WINNER)ABOUT PROPERTYGURU GROUPPropertyGuru is Southeast Asia’s leading1 PropTech company, and the preferred destination for over 32 million property seekers monthly2 to connect with over 50,000 agents3 monthly to find their dream home. PropertyGuru empowers property seekers with more than 2.1 million real estate listings4, in-depth insights, and solutions that enable them to make confident property decisions across Singapore, Malaysia, Thailand, and Vietnam.PropertyGuru.com.sg was launched in Singapore in 2007 and since then, PropertyGuru Group has made the property journey a transparent one for property seekers in Southeast Asia. In the last 18 years, PropertyGuru has grown into a high-growth PropTech company with a robust portfolio including leading property marketplaces and award-winning mobile apps across its markets in Singapore, Malaysia, Vietnam, and Thailand as well as the region’s biggest and most respected industry recognition platform – PropertyGuru Asia Property Awards, events, and publications across Asia.For more information, please visit: PropertyGuruGroup.com; PropertyGuru Group on LinkedIn.(1) Based on SimilarWeb data between July 2024 and December 2024.(2) Based on Google Analytics data between July 2024 and December 2024.(3) Based on data between October 2024 and December 2024.(4) Based on data between July 2024 and December 2024.PROPERTYGURU CONTACTS:General Enquiries:Richard Allan Aquino, Head of Brand & Marketing ServicesM: +66 92 954 4154E: allan@propertyguru.com Sales, Nominations, & Sponsorships:Udomluk Suwan, Sales DirectorM: +66 87 699 4433E: may@propertyguru.comMedia & Partnerships:Nate Dacua, Senior Manager, Media and Marketing ServicesM: +66 92 701 2510E: nate@propertyguru.comPiyachanok Raungpaka, Senior Media & Marketing Services ExecutiveM: +66 94 887 5163E: piyachanok@propertyguru.com Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO, Japan, Jan 13, 2026 - (JCN Newswire via SeaPRwire.com) - Honda Motor Co., Ltd. today announced that it will adopt a new H mark with refreshed design as the new symbol representing Honda automobile business. Since its first adoption in 1963 as a symbol to represent Honda automobiles, the H mark has always been used for Honda automobile products and business activities, while undergoing several design changes over the years.The H mark design was refreshed in conjunction with the development of next-generation EVs, including the Honda 0 Series, which are being developed with the determination to “create new EVs from ‘zero’ by going back to the starting point of Honda as an automaker.” Honda refreshed the H mark design to express its commitment to the transformation of the company as well as its corporate attitude of going beyond the origin of Honda and constantly pursuing new challenges and advancements. The new design expression, like two outstretched hands, represents the commitment of Honda to augment the possibilities of mobility and sincerely serve the needs of the customers of Honda automobile business.The new H mark is scheduled to be applied to next-generation EVs, and next-generation hybrid-electric (HEV) models starting with the models to be introduced to the market in 2027 and beyond.New H mark that represents Honda automobile businessMoreover, Honda will expand the use of the new H mark to represent Honda automobile business as a whole, including not only automobile products but other customer touchpoints such as dealership locations, communication initiatives and automobile motorsports activities. The automobile market is currently undergoing a major transformation with electrification and application of intelligent technologies. The new H mark will represent the “second founding”, which Honda is pursing with strong determination to lead the way during this period of transformation by offering new value that goes beyond customer expectations with cutting-edge technology and ideas without being bound by conventional ideas, practices and ways of doing things. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com

TOKYO and NEW YORK, NY., Jan 13, 2026 - (JCN Newswire via SeaPRwire.com) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”), a human-centered global leading research-based pharmaceutical company working in the neurology and oncology therapeutic areas, and Nuvation Bio Inc. (NYSE: NUVB, Corporate Headquarters: New York, NY, CEO: David Hung, M.D., “Nuvation Bio”), a global oncology company focused on tackling some of the toughest challenges in cancer treatment, today announced an exclusive license and collaboration agreement that significantly expands the long-term global footprint of taletrectinib (generic name, marketed as IBTROZI® in the U.S. and Japan). Taletrectinib is a highly selective, next-generation oral treatment currently approved for patients living with advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in the U.S., China, and Japan. Eisai will now have exclusive development, registration and commercialization rights for taletrectinib for the treatment of ROS1+ NSCLC in Europe, the Middle East, North Africa, Russia, Turkey, Canada, Australia, New Zealand, Singapore, the Philippines, Indonesia, Thailand, Malaysia, Vietnam and India. Nuvation Bio will continue to lead global development and retain full U.S. commercial rights, maintaining its strong focus on U.S. launch activities and ongoing pivotal studies of taletrectinib across early- and late-stage ROS1+ NSCLC“Our partnership with Eisai represents a major global expansion milestone for taletrectinib, strengthening the long-term potential of this clinically meaningful treatment option for even more patients living with ROS1+NSCLC,” said David Hung, M.D., Founder, President, and Chief Executive Officer of Nuvation Bio. “With Eisai’s world-class infrastructure and track record of bringing innovative medicines to market in major regions, we believe the expanse of this collaboration illustrates the commercial potential of taletrectinib while accelerating the opportunity for providers and patients around the world to access this important treatment option.”Under the terms of the exclusive license and collaboration agreement, Eisai will pay EUR 50 million (approx. USD 60 million) upfront and up to EUR 145 million (approx. USD 170 million) in regulatory and commercial milestone payments, as well as double-digit tiered royalties up to the high-teens as a percentage of future net sales in the licensed territories. Following the upfront payment, Eisai will paythe first milestone payment of EUR 25 million (approx. USD 30 million) from this transaction upon achievement of EU regulatory approval (conditional or full) of taletrectinib. The USD amounts are approximated based on an exchange rate of EUR1= USD1.2. Eisai anticipates no changes to its consolidated financial forecast for the period ending March 31, 2026.“With its efficacy and safety profile, we believe taletrectinib has the potential to become a standard of care for patients with ROS1+ NSCLC in the EU and beyond, as it is already becoming the standard of care in the U.S. just six months from approval,” said Terushige Iike, Chief Business Officer of Eisai Co., Ltd. “We are thrilled to partner with Nuvation Bio and prioritize taletrectinib as our flagship oncology product in NSCLC, bringing this innovative medicine to patients as quickly as possible.”A Marketing Authorization Application (MAA) for the treatment of advanced ROS1+ NSCLC is expected to be filed in Europe in the first half of 2026. Additional filings are then planned for Canada and other regions.In June 2025, the U.S. Food and Drug Administration (FDA) granted full approval to taletrectinib for the treatment of locally advanced or metastatic ROS1+ NSCLC across lines of therapy, following a Priority Review and double Breakthrough Therapy designations. Taletrectinib is also approved for patients with advanced ROS1+ NSCLC in Japan, where it is marketed by Nippon Kayaku, and in China, where it is marketed by Innovent Biologics under the brand name DOVBLERON®.MEDIA CONTACTSEisai Co., Ltd.Public Relations DepartmentTEL: +81 (0)3-3817-5120Nuvation Bio Inc.Kaitlyn Nealymedia@nuvationbio.comINVESTOR CONTACTSEisai Co., Ltd.Investor Relations DepartmentTEL: +81 (0) 3-3817-5122Nuvation Bio Inc.JR DeVitair@nuvationbio.comAbout ROS1+ NSCLCEach year, more than one million people globally are diagnosed with non-small cell lung cancer (NSCLC), the most common form of lung cancer. It is estimated that approximately 2% of patients with NSCLC have ROS1+ disease. About 35% of patients newly diagnosed with metastatic ROS1+ NSCLC have tumors that have spread to their brain. The brain is also the most common site of disease progression, with about 50% of previously treated patients developing central nervous system (CNS) metastases.About TaletrectinibTaletrectinib is an oral, potent, CNS-active, selective, next-generation ROS1 inhibitor therapy. On June 11, 2025, following Priority Review and Breakthrough Therapy designations for both TKI-naïve and TKI-pretreated disease, the U.S. Food and Drug Administration (FDA) approved taletrectinib for the treatment of adult patients with locally advanced or metastatic ROS1+ NSCLC. Learn more about taletrectinib in the U.S. at IBTROZI.com.About Eisai Co., Ltd.Eisai's Corporate Concept is "to give first thought to patients and people in the daily living domain, and to increase the benefits that health care provides." Under this Concept (also known as human health care (hhc) Concept), we aim to effectively achieve social good in the form of relieving anxiety over health and reducing health disparities. With a global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to create and deliver innovative products to target diseases with high unmet medical needs, with a particular focus in our strategic areas of Neurology and Oncology.In addition, we demonstrate our commitment to the elimination of neglected tropical diseases (NTDs), which is a target (3.3) of the United Nations Sustainable Development Goals (SDGs), by working on various activities together with global partners.For more information about Eisai, please visit www.eisai.com (for global headquarters: Eisai Co.,Ltd.), and connect with us on X, LinkedIn and Facebook. The website and social media channels are intended for audiences outside of the UK and Europe. About Nuvation Bio Nuvation Bio is a global oncology company focused on tackling some of the toughest challenges in cancer treatment with the goal of developing therapies that create a profound, positive impact on patients’ lives. Our diverse pipeline includes taletrectinib (IBTROZI®), a next-generation ROS1 inhibitor; safusidenib, a brain-penetrant IDH1 inhibitor; NUV-868, a BD2-selective BET inhibitor; and an innovative drug-drug conjugate (DDC) program.Nuvation Bio was founded in 2018 by biopharma industry veteran David Hung, M.D., who previously founded Medivation, Inc., which brought to patients one of the world’s leading prostate cancer medicines. Nuvation Bio has offices in New York, San Francisco, Boston, and Shanghai. For more information, visit www.nuvationbio.com or follow the company on LinkedIn and X (@nuvationbioinc).About the TRUST Clinical ProgramThe TRUST clinical program comprises three registrational studies evaluating the safety and efficacy of taletrectinib. TRUST-I (NCT04395677) and TRUST-II (NCT04919811) are Phase 2 single-arm studies evaluating taletrectinib for the treatment of adults with advanced ROS1+ NSCLC in China (N=173) and globally (N=189), respectively. The primary endpoint of both studies is confirmed objective response rate (cORR) as assessed by an independent review committee. TRUST-IV (NCT07154706) is a Phase 3 placebo-controlled study evaluating taletrectinib for the adjuvant treatment of adults with resected early-stage ROS1+ NSCLC. The study will enroll approximately 180 patients in the U.S., Canada, Europe, Japan and China. The primary endpoint is disease-free survival as determined by investigator, and the primary completion date is estimated to be in 2030. Nuvation Bio is also sponsoring TRUST-III (NCT06564324), a confirmatory randomized Phase 3 study evaluating taletrectinib versus crizotinib in 138 patients in China with advanced ROS1+ NSCLC who have not previously received ROS1 TKIs.U.S. IndicationIBTROZI is indicated for the treatment of adult patients with locally advanced or metastatic ROS1+ nonsmall cell lung cancer (NSCLC).IMPORTANT SAFETY INFORMATION FOR IBTROZI® (taletrectinib)WARNINGS AND PRECAUTIONSHepatotoxicity: Hepatotoxicity, including drug-induced liver injury and fatal adverse reactions, can occur. 88% of patients experienced increased AST, including 10% Grade 3/4. 85% of patients experienced increased ALT, including 13% Grade 3/4. Fatal liver events occurred in 0.6% of patients. Median time to first onset of AST or ALT elevation was 15 days (range: 3 days to 20.8 months).Increased AST or ALT each led to dose interruption in 7% of patients and dose reduction in 5% and 9% of patients, respectively. Permanent discontinuation was caused by increased AST, ALT, or bilirubin each in 0.3% and by hepatotoxicity in 0.6% of patients.Concurrent elevations in AST or ALT ≥3 times the ULN and total bilirubin ≥2 times the ULN, with normal alkaline phosphatase, occurred in 0.6% of patients.Interstitial Lung Disease (ILD)/Pneumonitis: Severe, life-threatening, or fatal ILD or pneumonitis can occur. ILD/pneumonitis occurred in 2.3% of patients, including 1.1% Grade 3/4. One fatal ILD case occurred at the 400 mg daily dose. Median time to first onset of ILD/pneumonitis was 3.8 months (range: 12 days to 11.8 months).ILD/pneumonitis led to dose interruption in 1.1% of patients, dose reduction in 0.6% of patients, and permanent discontinuation in 0.6% of patients.QTc Interval Prolongation: QTc interval prolongation can occur, which can increase the risk for ventricular tachyarrhythmias (e.g., torsades de pointes) or sudden death. IBTROZI prolongs the QTc interval in a concentration-dependent manner.In patients who received IBTROZI and underwent at least one post baseline ECG, QTcF increase of >60 msec compared to baseline and QTcF >500 msec occurred in 13% and 2.6% of patients, respectively. 3.4% of patients experienced Grade ≥3. Median time from first dose of IBTROZI to onset of ECG QT prolongation was 22 days (range: 1 day to 38.7 months). Dose interruption and dose reduction each occurred in 2.8% of patients.Significant QTc interval prolongation may occur when IBTROZI is taken with food, strong and moderate CYP3A inhibitors, and/or drugs with a known potential to prolong QTc. Administer IBTROZI on an empty stomach. Avoid concomitant use with strong and moderate CYP3A inhibitors and/or drugs with a known potential to prolong QTc.Hyperuricemia: Hyperuricemia can occur and was reported in 14% of patients, with 16% of these requiring urate-lowering medication without pre-existing gout or hyperuricemia. 0.3% of patients experienced Grade ≥3. Median time to first onset was 2.1 months (range: 7 days to 35.8 months). Dose interruption occurred in 0.3% of patients.Myalgia with Creatine Phosphokinase (CPK) Elevation: Myalgia with or without CPK elevation can occur. Myalgia occurred in 10% of patients. Median time to first onset was 11 days (range: 2 days to 10 months).Concurrent myalgia with increased CPK within a 7-day time period occurred in 0.9% of patients. Dose interruption occurred in 0.3% of patients with myalgia and concurrent CPK elevation.Skeletal Fractures: IBTROZI can increase the risk of fractures. ROS1 inhibitors as a class have been associated with skeletal fractures. 3.4% of patients experienced fractures, including 1.4% Grade 3. Some fractures occurred in the setting of a fall or other predisposing factors. Median time to first onset of fracture was 10.7 months (range: 26 days to 29.1 months). Dose interruption occurred in 0.3% of patients.Embryo-Fetal Toxicity: Based on literature, animal studies, and its mechanism of action, IBTROZI can cause fetal harm when administered to a pregnant woman.ADVERSE REACTIONSAmong patients who received IBTROZI, the most frequently reported adverse reactions (≥20%) were diarrhea (64%), nausea (47%), vomiting (43%), dizziness (22%), rash (22%), constipation (21%), and fatigue (20%). The most frequently reported Grade 3/4 laboratory abnormalities (≥5%) were increased ALT (13%), increased AST (10%), decreased neutrophils (5%), and increased creatine phosphokinase (5%). DRUG INTERACTIONSStrong and Moderate CYP3A Inhibitors/CYP3A Inducers and Drugs that Prolong the QTc Interval: Avoid concomitant useGastric Acid Reducing Agents: Avoid concomitant use with PPIs and H2 receptor antagonists. If an acid-reducing agent cannot be avoided, administer locally acting antacids at least 2 hours before or 2 hours after taking IBTROZI.OTHER CONSIDERATIONSPregnancy: Please see important information in Warnings and Precautions under EmbryoFetal Toxicity. Lactation: Advise women not to breastfeed during treatment and for 3 weeks after the last dose.Effect on Fertility: Based on findings in animals, IBTROZI may impair fertility in males and females. The effects on animal fertility were reversible.Pediatric Use: The safety and effectiveness of IBTROZI in pediatric patients has not been established.Photosensitivity: IBTROZI can cause photosensitivity. Advise patients to minimize sun exposure and to use sun protection, including broad-spectrum sunscreen, during treatment and for at least 5 days after discontinuation.Please see accompanying full U.S. Prescribing Information.Forward-Looking Statements of Nuvation Bio Inc.Certain statements included in this press release that are not historical facts are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements are sometimes accompanied by words such as “believe,” “may,” “will,” “estimate,” “continue,” “anticipate,” “intend,” “expect,” “should,” “would,” “plan,” “predict,” “potential,” “seem,” “seek,” “future,” “outlook” and similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding IBTROZI’S therapeutic and commercial potential, our expectations for a MAA filing for IBTROZI in Europe and the timing thereof, and the receipt and timing of a regulatory and commercial milestone payment under our license and collaboration agreement with Eisai. These statements are based on various assumptions, whether or not identified in this press release, and on the current expectations of the management team of Nuvation Bio and are not predictions of actual performance. These forward-looking statements are subject to a number of risks and uncertainties that may cause actual results to differ from those anticipated by the forward looking statements, including but not limited to the challenges associated with conducting drug discovery and commercialization, and initiating or conducting clinical studies due to, among other things, difficulties or delays in the regulatory process, enrolling subjects or manufacturing or acquiring necessary products; the emergence or worsening of adverse events or other undesirable side effects; risks associated with preliminary and interim data, which may not be representative of more mature data; physician and patient behavior; and competitive developments. Risks and uncertainties facing Nuvation Bio are described more fully in its Form 10-Q filed with the SEC on November 3, 2025 under the heading “Risk Factors,” and other documents that Nuvation Bio has filed or will file with the SEC. You are cautioned not to place undue reliance on the forward-looking statements, which speak only as of the date of this press release. Nuvation Bio disclaims any obligation or undertaking to update, supplement or revise any forward-looking statements contained in this press release. Copyright 2026 JCN Newswire via SeaPRwire.com. All rights reserved. www.jcnnewswire.com